tim.hodson
Mon, 10/06/2025 – 12:44
Oct. 3, 2025 — IceCure Medical Ltd., developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, recently announced that the U.S. Food and Drug Administration has granted marketing authorization to IceCure’s De Novo application for the ProSense cryoablation system for the local treatment of breast cancer in patients ≥70 years of age with biologically low-risk tumors ≤1.5 cm in si…